Survival benefit and safety of the combinations of FOLFOXIRI &plusmn; bevacizumab versus the combinations of FOLFIRI &plusmn; bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

Original Research

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

Total article views		HTML views	PDF downloads	Totals
8,472	Dovepress*	7,361+	1,173	8,534
	PubMed Central*	1,111	418	1,529
	Totals	8,472	1,591	10,063
*Since 4 August 2016